display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - triple negative
mBC - TNBC - L2 - all populationmBC - TNBC - L2 - PDL1 positive
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-119 ... KEYNOTE-119 ... KEYNOTE-119 ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons